技術文章您現在的位置:首頁 > 技術文章 > BioXcell:InVivoMAb anti-mouse CD172a (SIRPα)單克隆抗體

BioXcell:InVivoMAb anti-mouse CD172a (SIRPα)單克隆抗體

更新時間:2025-03-18   點擊次數:126次

P84單克隆抗體,也被稱為CD172a抗體,可與信號調節蛋白α(SIRPα)反應。SIRPα蛋白是I型跨膜糖蛋白,在單核細胞、巨噬細胞和樹突狀細胞均有表達。此外,在神經元和中樞神經系統的一些其他組織也發現有SIRPα蛋白的表達。其配體CD47在多種細胞均有表達。

 

SIRPα和CD47參與調節由樹突狀細胞介導的T細胞的活化、中性粒細胞遷移和吞噬等過程。SIRPα蛋白可在巨噬細胞的細胞膜上進行橫向擴散并在吞噬性突觸中積累,與CD47結合后,抑制巨噬細胞的吞噬作用。

 

研究結果表明,使用anti-SIRPα抗體阻斷SIRPα與CD47相互作用,可抑制小鼠體內腫瘤的形成。此外,P84(CD172a)單克隆抗體在體內和體外均具有中和活性。

 

BioXcell最新推出InVivoMAb anti-mouse CD172a (SIRPα)單克隆抗體,助力腫瘤免疫檢查點研究。如需購買BioXcell公司產品,請聯系代理商欣博盛生物。

BE0322.jpg


產品信息:

產品貨號

BE0322

產品名稱

InVivoMAb   anti-mouse CD172a (SIRPα)

規格

1mg,5mg,25mg,   50mg, 100mg

克隆號

P84

同種型(Isotype)

Rat IgG1, κ

免疫原(Immunogen)

Mouse brain   membrane protein

成分(Formulation)

PBS, pH   7.0  

Contains no   stabilizers or preservatives

內毒素(Endotoxin)

<2EU/mg (<0.002EU/μg)

Determined   by LAL gel clotting assay

純度(Purity)

>95%

Determined   by SDS-PAGE

無菌(Sterility)

0.2 μM   filtered

生產(Production)

Purified   from tissue culture supernatant in an animal free facility

純化(Purification)

Protein A

保存(Storage)

Undiluted at   4°C in the dark

應用(Reported Applications)

In   vivo SIRPα blocking

In   vitro SIRPα blocking

Western blot


Application References:

Yanagita, T., et al. (2017). 'Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy.' JCI Insight 2(1): e89140. 

Koskinen, C., et al. (2013). 'Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein alpha (SIRPalpha) signaling.' J Biol Chem 288(41): 29333-29344. 

Teraoka, Y., et al. (2013). 'Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalpha inhibitory signaling in mice.' PLoS One 8(3): e58359. 

Zen, K., et al. (2013). 'Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state.' Nat Commun 4: 2436.

Lundberg, P., et al. (2007). 'Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction.' Biochem Biophys Res Commun 352(2): 444-448. 

Oldenborg, P. A., et al. (2001). 'CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.' J Exp Med 193(7): 855-862.

日韩国产欧美视频一区二区三区